RGRobert I. Griffiths

Robert I. Griffiths

*This is an algorithmically generated author record based on publicly available information.

Robert I. Griffiths has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Medical Resource Use and Cost of Venlafaxine or Tricyclic Antidepressant Therapy

    by Robert I. Griffiths, Erin M. Sullivan, Richard G. Frank, Michael J. Strauss, Robert J. Herbert, Jon Clouse, Howard H. Goldman


  • Medical-Resource Use for Suspected Tuberculosis in a New York City Hospital

    by Robert I. Griffiths, Charles L. Hyman, Samy I. McFarlane, Guillermo R. Saurina, Jane E. Anderson, Theodore O'BRien, Caroline Popper, Margaret M. McGrath, Robert J. Herbert, Marcelino F. Sierra

    Objective: To compare resource use by diagnostic outcome among hospital admissions during which tuberculosis (TB) was suspected. Design: Retrospective study based on chart review and microbiology laboratory data. Setting: The department of medicine in a municipal hospital serving central Brooklyn, New York. Participants: We identified all adult admissions in 1993 during which TB was suspected. We assigned each admission to one of four mutually exclusive groups defined by the results of microbiological tests (acid-fast bacilli [AFB] smear and culture): culture-positive and smear-positive (C + S +); culture-positive and smear-negative (C + S−); culture-negative and smear-positive (C−S+); or culture-negative and smear-negative (C−S−). Each admission was divided into two separate periods to which the utilization of medical resources was assigned: the diagnostic and the postdiagnostic periods, which were separated by the date of receipt of the first definitive culture report. Results: Data on 519 admissions (93 C+S+; 57 C+S−; 30 C−S+; and 339 C−S−) were analyzed. Although C+S+ were more likely than other groups to have an admitting diagnosis of TB, approximately one quarter of the admissions without TB (C−S+, C−S−) were admitted with the principal diagnosis of TB. For the four groups, C+S+, C+S−, C−S+, and C−S−, the respective rates of TB isolation and anti-TB treatment, and median lengths of isolation were 98%, 87%, and 34 days; 74%, 74%, and 7 days; 83%, 83%, and 15 days; and 44%, 29%, and 0 days. During the diagnostic period, the rate and length of isolation were similar in the AFB-smear—positive groups (C+S+ and C−S+). We estimated that admissions without culture-proven TB (C−S+ and C−S−) accounted for 3,174 (36%) of the 8,712 days of TB isolation expended and for 65% of the 16,671 days of anti-TB treatment. The vast majority of this resource consumption (2,737 [86%] of 3,174 days of isolation) occurred during the diagnostic period before a definitive culture result was known. Conclusions: Our results suggest that prolonged diagnostic uncertainty and misclassification of cases due to false-positive and false-negative smears are associated with substantial medical-resource consumption. New diagnostic modalities that reduce the period of diagnostic uncertainty could reduce the utilization of resources later found to be unnecessary


  • Pharmacoeconomic Analysis of 3 Treatment Strategies for Cytomegalovirus Retinitis in Patients with AIDS

    by Robert I. Griffiths, Giselle C. Bleecker, Douglas A. Jabs, Douglas T. Dieterich, Laura Coleson, Debbie Winters, Richard Wolitz, Earl P. Steinberg


    • 1 March 1996
      • Vol. 10  (3) , 285

    Economic savings and costs of periodic mammographic screening in the workplace.

    by R I Griffiths, M M McGrath, V G Vogel

    This article discusses the costs and benefits of mammographic screening in the workplace. The cost of mammography itself and of diagnostic work-up are two of the largest costs involved. Therefore, the most efficient approach to providing mammography depends on the number of employees receiving mammography; and the diagnostic accuracy of mammography and underlying incidence of breast cancer in the screened population strongly influence the number of suspicious mammograms that are not associated with breast cancer. The health benefit of mammographic screening is due to reduced mortality and morbidity through early detection and more effective treatment, which may also result in economic savings if early-stage cancer is less expensive to treat. However, the total lifetime cost of treating early-stage cancer may be greater than treating late-stage cancer because of improved survival of early-stage patients. Thus, although periodic mammographic screening is not likely to result in overall economic savings, in many populations of working-age women, especially those with identifiable risk factors, screening is cost-effective because the expenditure required to save a year of life through early detection of breast cancer is low compared to other types of health services for which employers commonly pay.